Yelin Lapidot Holdings Management Ltd. Lowers Stock Position in Sol-Gel Technologies Ltd. $SLGL

Yelin Lapidot Holdings Management Ltd. decreased its position in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) by 92.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,753 shares of the company’s stock after selling 209,325 shares during the period. Yelin Lapidot Holdings Management Ltd. owned about 0.64% of Sol-Gel Technologies worth $131,000 at the end of the most recent quarter.

Analyst Upgrades and Downgrades

SLGL has been the subject of several recent analyst reports. Wall Street Zen lowered Sol-Gel Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Zacks Research raised Sol-Gel Technologies to a “hold” rating in a research note on Tuesday, October 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Sol-Gel Technologies in a research report on Wednesday, October 8th. Finally, HC Wainwright boosted their price target on shares of Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, October 27th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $50.00.

Sol-Gel Technologies Stock Down 7.7%

Shares of SLGL opened at $30.18 on Friday. Sol-Gel Technologies Ltd. has a 52-week low of $4.01 and a 52-week high of $52.26. The stock has a market cap of $84.07 million, a PE ratio of -24.53 and a beta of 1.35. The firm’s fifty day moving average is $32.41 and its two-hundred day moving average is $17.73.

Sol-Gel Technologies (NASDAQ:SLGL) last posted its quarterly earnings results on Friday, August 15th. The company reported $4.17 earnings per share for the quarter, topping the consensus estimate of ($0.67) by $4.84. Sol-Gel Technologies had a negative net margin of 14.25% and a negative return on equity of 11.80%. The firm had revenue of $17.26 million for the quarter, compared to the consensus estimate of $2.86 million. As a group, research analysts anticipate that Sol-Gel Technologies Ltd. will post -0.28 earnings per share for the current year.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.